Yu-Hsin Lin - 18 Mar 2026 Form 3 Insider Report for BELITE BIO, INC (BLTE)

Role
Chief Executive Officer, Director
Signature
/s/ Yu-Hsin Lin
Issuer symbol
BLTE
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 14:24:01 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lin Yu-Hsin Chief Executive Officer, Director 12750 HIGH BLUFF DRIVE, SUITE 475, SAN DIEGO /s/ Yu-Hsin Lin 18 Mar 2026 0001965964

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BLTE American depositary share 180,134 18 Mar 2026 Direct F1
holding BLTE Ordinary Share 172,949 18 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 206,954 $0.4386 Direct F2
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 27,778 $6.00 Direct F3
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 166,667 $14.45 Direct F4
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 208,334 $48.46 Direct F5
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 200,000 $54.88 Direct F6
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 40,000 $77.40 Direct F7
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 80,000 $93.02 Direct F8
holding BLTE Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 150,000 $158.36 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.
F2 The option to purchase 206,954 ordinary shares had vested prior to March 18, 2026.
F3 The option to purchase 27,778 ordinary shares had vested prior to March 18, 2026.
F4 The option to purchase 145,833 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 20,834 ordinary shares in five equal and continuous monthly installments at the end of each month from March 2026 to July 2026, subject to continued service to the Issuer on each such date.
F5 The option to purchase 83,334 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 125,000 ordinary shares in 18 monthly equal and continuous installments at the end of each month from March 2026 to August 2028, subject to continued service to the Issuer on each such date.
F6 The option shall vest as to 200,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following February 12, 2025, subject to continued service to the Issuer on each such date.
F7 The option to purchase 40,000 ordinary shares had vested prior to March 18, 2026.
F8 The option to purchase 80,000 ordinary shares had vested prior to March 18, 2026.
F9 The option shall vest (i) as to 50,000 ordinary shares on January 9, 2027, (ii) as to 50,000 ordinary shares on January 9, 2028, and (iii) as to 50,000 ordinary shares on January 9, 2029.

Remarks:

Exhibit 24 - Power of Attorney